API | opicinumab

opicinumab Report issue

Biologics mAb Experimental

AACT ChEMBL

Active Ingredient History

NOW

Opicinumab (BIIB033) is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis (AON), and other associated demyelinating diseases. A biologic drug, it is designed to function as a LINGO-1 protein antagonist, known as "Anti-Lingo-1". ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

None

opicinumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

anti-lingo | biib033 | biib-033 | opicinumab

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Central Nervous System Diseases (Phase 1)

Healthy Volunteers (Phase 1)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Neuritis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue